Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nadolol
Drug ID BADD_D01512
Description Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects.[A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922]
Indications and Usage Used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension.
Marketing Status Prescription; Discontinued
ATC Code C07AA12
DrugBank ID DB01203
KEGG ID D00432
MeSH ID D009248
PubChem ID 39147
TTD Drug ID D05SHK
NDC Product Code 68382-733; 72664-211; 51927-2776; 70518-1755; 70518-2139; 67787-348; 59762-0810; 27505-102; 0781-8006; 59762-0811; 51079-812; 76282-348; 68382-732; 68001-318; 69238-1124; 69238-1125; 42973-148; 76282-347; 70771-1090; 10135-687; 67787-349; 59762-0812; 0378-1132; 0781-8004; 0904-7070; 23155-732; 12780-0154; 76282-349; 0378-0028; 27505-101; 72664-212; 70771-1089; 27505-100; 0781-8005; 76385-135; 67787-347; 23155-730; 60687-302; 10135-686; 50787-0008; 59651-252; 71335-1972; 70771-1091; 69238-1123; 68001-317; 76385-133; 23155-731; 0378-1171; 59651-251; 68001-319; 78670-100; 60687-313; 10135-688; 63629-6942; 76385-134; 68382-734; 69575-4016; 72664-213; 71335-0697; 0904-7071; 69097-869; 69097-867; 69097-868; 78670-101; 65015-718; 51079-813
Synonyms Nadolol | SQ-11725 | SQ 11725 | SQ11725 | Corgard | Solgol
Chemical Information
Molecular Formula C17H27NO4
CAS Registry Number 1403-22-1
SMILES CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinus bradycardia02.03.03.0090.001515%
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.0060.003788%
Swelling face23.04.01.018; 10.01.05.018--Not Available
Syncope17.02.04.008; 02.01.02.008; 24.06.02.0120.001515%
Tinnitus17.04.07.004; 04.04.01.002--
Torsade de pointes02.03.04.0050.000593%Not Available
Ventricular extrasystoles02.03.04.007--Not Available
Ventricular tachycardia02.03.04.0100.001515%
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Mental status changes19.07.01.0010.000593%Not Available
Hypoglycaemic seizure17.12.03.015; 14.06.03.002; 05.06.03.0020.003788%Not Available
Tachyarrhythmia02.03.02.0080.000593%Not Available
Affect lability19.04.01.001--Not Available
Vascular insufficiency24.04.02.014--Not Available
Purpura non-thrombocytopenic01.01.04.006--Not Available
Pulseless electrical activity02.03.04.0200.001515%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Embolism24.01.01.009--
Abnormal behaviour19.01.01.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Neuropsychological test abnormal13.07.06.001--Not Available
Oropharyngeal discomfort22.02.05.027; 07.05.05.008--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
The 4th Page    First    Pre   4    Total 4 Pages